Zydus Cadila would be making a presentation on Lipagyln at the American Association of Clinical Endocrinologists (AACE) 24 th Annual Scientific and Clinical Congress to be held from 13 th to 17th of May 2015 at Nashville, Tennesse, USA. Further, the abstract titled ‘9 month safety and efficacy of Saroglitazar in Diabetic Dyslipidemia has been accepted for late breaking presentation at the AACE meeting.
Lipagyln was launched in September 2013 in India for treating Hypertriglyceridemia and Diabetic Dyslipidemia in patients with Type 2 diabetes not controlled by statins. Since then more than 80,000 patients are availing this drug with a prescriber base over 3500 diabetologists, cardiologists and physicians.
Zydus Cadila is an innovation, global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: